Evidence map›Paper›PMID 42573768›Full record

ArticlePediatric cardiology2026

Safety and Tolerability of Chronic Carvedilol in Pediatric Dilated Cardiomyopathy: A Report from the Pediatric Cardiomyopathy Registry.

Neha Bansal, Joseph W Rossano, Ling Shi, Daphne T Hsu, Charles E Canter, Elfriede Pahl, Jeffrey A Towbin, Steven D Colan, Paul F Kantor, Melanie D Everitt and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Neha BansalDivision of Pediatric Cardiology, Hassenfeld Children's Hospital at NYU Langone Health, New York, NY, USA.
Joseph W RossanoChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
Ling ShiUniversity of Massachusetts, Boston, Boston, MA, USA.
Daphne T HsuChildren's Hospital at Montefiore, Bronx, NY, USA.
Charles E CanterSt. Louis Children's Hospital, St. Louis, MO, USA.
Elfriede PahlAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Jeffrey A TowbinUniversity of Tennessee Health Science Center, Department of Pediatrics, Memphis, TN, USA.
Steven D ColanDepartment of Cardiology, Boston Children's Hospital, Boston, MA, USA.
Paul F KantorChildren's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA.
Melanie D EverittDepartment of Pediatrics, Children's Hospital of Colorado, University of Colorado Anschutz, Aurora, CO, USA.
Jean A BallwegHelen DeVos Children's Hospital, Grand Rapids, MI, USA.
Kathleen E SimpsonDepartment of Pediatrics, Children's Hospital of Colorado, University of Colorado Anschutz, Aurora, CO, USA.
Steven E LipshultzDepartment of Pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA. slipshul@buffalo.edu.

Funding

NHLBI NIH HHS HL053392
6 · The paper itself

Abstract

Long-term studies on safety of beta-blockers in pediatric heart failure (HF) are scant. We describe the safety profile, dose ranges, and tolerability of carvedilol in pediatric dilated cardiomyopathy (DCM). The Pediatric Cardiomyopathy Registry (PCMR) was used to identify patients with DCM, treated with carvedilol from 1997 to 2005. Descriptive statistics were analyzed and echocardiographic parameters were compared longitudinally using ANOVA. Total 118 patients were included with median age 4.4 years (interquartile range (IQR) 1.0-13.3). The etiology of DCM was idiopathic (66%), myocarditis (14%), familial DCM (21%). Majority (63%) had symptoms of HF at diagnosis and were on an angiotensin-converting enzyme inhibitor (ACEi) (95%) at carvedilol initiation. The mean ± standard deviation (SD) carvedilol dose at 1 year was 0.38 ± 0.44 mg/kg/dose. The median duration of carvedilol therapy studied was 361 days (IQR 101-958) with 18% of the patients treated for > 3 years. Few patients (< 10%) had blood pressure or heart rate below safety thresholds with no admission for hypotension or bradycardia. Only 4 patients discontinued carvedilol for bradycardia (n = 1), fatigue (n = 1), poor LV function (n = 1) and worsening renal function (n = 1). Mean left ventricular shortening fraction (LVFS) was 16% ± 8 at carvedilol initiation (n = 98), 21% ± 9 at 1 year (n = 49) and 23% ± 9 at 2 years (n = 20) post-carvedilol initiation, suggesting a possible clinical benefit (p < 0.01). These results provide safety data for chronic carvedilol use in children and show a low prevalence of discontinuation for adverse events. Further study of the long-term remodeling effects of chronic beta-blocker use in pediatric HF is required.

Indexed as

Beta blockerCarvedilolDilated cardiomyopathyHeart failurePediatrics

Identifiers

PMID42573768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.